Vesicular Monoamine Transporter 2 (VMAT2) Pathway in Parkinson's Disease

Migration, Crosslink

📖

Vesicular Monoamine Transporter 2 (VMAT2) Pathway in Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-vmat2-pathway-parkinsons

📖 Wiki Page

mechanisms3096 wordssynced 2026-04-02

Vesicular Monoamine Transporter 2 (VMAT2) Pathway in Parkinson's Disease

Overview

Vesicular Monoamine Transporter 2 (VMAT2), encoded by the SLC18A2 gene, is responsible for packaging dopamine and other monoamines into synaptic vesicles. VMAT2 is essential for safe storage and release of neurotransmitters, and its dysfunction contributes to Parkinson's Disease pathogenesis through impaired dopamine handling and increased vulnerability to neurotoxins. This page provides a comprehensive analysis of VMAT2 biology, its role in Parkinson's disease (PD) pathogenesis, and therapeutic targeting strategies.

The vesicular monoamine transporter family includes two isoforms: VMAT1 (encoded by SLC18A1) and VMAT2 (encoded by SLC18A2). While VMAT1 is primarily expressed in endocrine cells and peripheral neurons, VMAT2 is the dominant isoform in the central nervous system (CNS) and is expressed exclusively in monoaminergic neurons including dopaminergic, serotonergic, noradrenergic, and histaminergic neurons[@eiden2011][@lohr2020]. VMAT2-mediated vesicular sequestration of neurotransmitters represents a critical neuroprotective mechanism that prevents cytoplasmic accumulation of potentially toxic monoamines and their oxidative metabolites.

Gene and Protein Information

...

Vesicular Monoamine Transporter 2 (VMAT2) Pathway in Parkinson's Disease

Overview

Vesicular Monoamine Transporter 2 (VMAT2), encoded by the SLC18A2 gene, is responsible for packaging dopamine and other monoamines into synaptic vesicles. VMAT2 is essential for safe storage and release of neurotransmitters, and its dysfunction contributes to Parkinson's Disease pathogenesis through impaired dopamine handling and increased vulnerability to neurotoxins. This page provides a comprehensive analysis of VMAT2 biology, its role in Parkinson's disease (PD) pathogenesis, and therapeutic targeting strategies.

The vesicular monoamine transporter family includes two isoforms: VMAT1 (encoded by SLC18A1) and VMAT2 (encoded by SLC18A2). While VMAT1 is primarily expressed in endocrine cells and peripheral neurons, VMAT2 is the dominant isoform in the central nervous system (CNS) and is expressed exclusively in monoaminergic neurons including dopaminergic, serotonergic, noradrenergic, and histaminergic neurons[@eiden2011][@lohr2020]. VMAT2-mediated vesicular sequestration of neurotransmitters represents a critical neuroprotective mechanism that prevents cytoplasmic accumulation of potentially toxic monoamines and their oxidative metabolites.

Gene and Protein Information

| Property | Value |
|----------|-------|
| Gene Symbol | SLC18A2 |
| Protein Name | Vesicular Monoamine Transporter 2 |
| Alternative Names | VMAT2, VAT2, Monoamine Transporter, Solute Carrier Family 18 Member 2 |
| Chromosomal Location | 10q25.3 |
| Protein Class | Vesicular neurotransmitter transporter (VMAT family) |
| UniProt ID | Q9H3Z1 |
| Molecular Weight | ~56 kDa (557 amino acids) |
| Subcellular Location | Synaptic vesicles, secretory granules, dense-core vesicles |
| Expression | All monoaminergic neurons (dopaminergic, serotonergic, noradrenergic, histaminergic) |
| Tissue Specificity | Brain (highest in substantia nigra, striatum, locus coeruleus), adrenal medulla |

Protein Structure

VMAT2 is an integral membrane protein with 12 transmembrane domains that forms a proton-dependent antiport transporter. The protein contains multiple substrate binding sites and is regulated by phosphorylation, protein interactions, and post-translational modifications. Structural studies have revealed the transport mechanism involves conformational changes that alternate between outward-facing and inward-facing states, with proton coupling driving monoamine transport against concentration gradients[@yaffe2018]. The N-terminus and C-terminus of VMAT2 face the cytoplasm, allowing for regulatory protein interactions and post-translational modifications. Key phosphorylation sites including serine and threonine residues modulate VMAT2 activity in response to neuronal signaling[@torres2006].

The vesicular transporter differs critically from plasma membrane monoamine transporters (SERT, DAT, NET) in several fundamental aspects. While plasma membrane transporters mediate reuptake of neurotransmitters from the synaptic cleft, VMAT2 packages neurotransmitters into vesicles for activity-dependent release. This difference has profound implications for drug development and understanding neurotransmitter homeostasis[@kristensen2011].

Normal Physiological Function

Vesicular Packaging and Neuroprotection

VMAT2 serves multiple critical functions in monoaminergic neurons[@deutch2020][@goldstein2010]:

Dopamine Storage: Packages dopamine into synaptic vesicles for activity-dependent release

Neuroprotection: Sequesters dopamine away from cytoplasmic oxidative reactions that generate toxic metabolites

Quantal Release: Enables synaptic vesicle-dependent neurotransmitter release with precise temporal control

Neuromodulation: Regulates extracellular dopamine levels for proper motor control, reward processing, and cognitive function

The neuroprotective function of VMAT2 is particularly critical for dopaminergic neurons in the substantia nigra pars compacta (SNc), which are uniquely vulnerable in Parkinson's disease. These neurons express high levels of VMAT2 and rely heavily on vesicular sequestration to protect against dopamine's inherent toxicity[@bannon2000].

Transport Mechanism

VMAT2 operates through a proton gradient-dependent antiport mechanism[@edelman1998][@liu2019]:

Energy Coupling: Uses V-ATPase-generated proton gradient (H+ influx drives monoamine efflux)
Substrate Specificity: Transports dopamine, serotonin, norepinephrine, epinephrine, histamine, and trace amines
Stoichiometry: Typically 2 monoamine molecules transported per proton
Vesicular Loading: Achieves concentrations 10-100 fold higher in vesicles than in cytoplasm

The V-ATPase pump maintains the proton gradient across the vesicular membrane, consuming ATP to pump protons into the vesicle lumen. This creates an electrochemical gradient that drives the uptake of positively charged monoamine neurotransmitters in exchange for protons. The efficiency of this transport system is essential for normal neuronal function[@parsche2020].

Key Physiological Roles

Maintains cytoplasmic dopamine at low physiological levels (~1% of total dopamine)
Enables synchronous and quantal neurotransmitter release
Protects neurons against dopamine auto-oxidation and quinone formation
Supports normal motor function, reward learning, and endocrine regulation

Pathogenic Mechanisms in Parkinson's Disease

VMAT2 Changes in PD

Unlike the dopamine transporter (DAT), which shows marked reduction in early PD, VMAT2 is relatively preserved in early disease stages. However, progressive VMAT2 dysfunction occurs with disease progression through multiple mechanisms[@guo2019][@caudle2007][@miller2006]:

Transcriptional Downregulation: Reduced SLC18A2 gene expression in substantia nigra

Protein Misfolding: Impaired trafficking and degradation of mutant VMAT2

Oxidative Modification: VMAT2 oxidation impairs transport function

Alpha-Synuclein Interaction: Pathological alpha-synuclein disrupts VMAT2 function

Vesicular ATPase Dysfunction: Impaired proton gradient reduces VMAT2 activity

ER-Golgi Trafficking Defects: Impaired processing and localization

The relative preservation of VMAT2 compared to DAT in early PD has important implications for diagnostic imaging and understanding disease progression. While DAT imaging shows significant loss in early PD, VMAT2 binding remains relatively stable, making it a more specific marker for disease progression rather than diagnosis[@frey2010].

Molecular Mechanisms of VMAT2 Dysfunction

Mermaid diagram (expand to render)

Key Pathogenic Pathways

1. Impaired Dopamine Sequestration

Reduced VMAT2 function leads to cytoplasmic dopamine accumulation[@hastings2009][@goldstein2012]:

Dopamine auto-oxidizes to dopamine-quinones and dopaminochrome
Forms neuromelanin (protective at physiological levels, toxic when excessive)
Quinones modify proteins, lipids, and DNA causing cellular dysfunction
Oxidative stress damages mitochondria, ER, and other organelles
Modified proteins contribute to proteostatic stress and aggregation

The dopamine-quinone pathway is particularly relevant to PD pathogenesis. Dopamine-quinones can covalently modify cysteine residues on proteins, altering their function and promoting aggregation. Notably, alpha-synuclein contains multiple cysteine residues that may be modified by dopamine-quinones, potentially linking VMAT2 dysfunction to alpha-synuclein pathology[@conway2000].

2. Synaptic Vesicle Dysfunction

Alpha-synuclein pathology directly affects vesicular function[@volpicellidaley2021][@lotharius2002]:

Alpha-synuclein binds to synaptic vesicles with high affinity
Impairs vesicular release and recycling
Disrupts quantal transmission and neurotransmitter homeostasis
Promotes vesicle clustering and reduced mobility
Causes premature neurotransmitter release and impaired reuptake

The interaction between alpha-synuclein and synaptic vesicles is bidirectional. While alpha-synuclein pathology impairs vesicle function, VMAT2 dysfunction may promote alpha-synuclein aggregation through increased cytosolic dopamine and oxidative stress. This creates a feedforward pathological loop that accelerates disease progression[@venda2010].

3. Mitochondrial Vulnerability

Cytosolic dopamine affects mitochondrial function[@perier2009][@exner2012]:

Dopamine-quinones inhibit mitochondrial complex I
Increases sensitivity to environmental neurotoxins (MPTP, rotenone)
Promotes mitochondrial permeability transition pore opening
Triggers apoptotic cascade in dopaminergic neurons
Impairs mitochondrial dynamics (fission/fusion)
Reduces mitochondrial biogenesis

The sensitivity of dopaminergic neurons to mitochondrial toxins is well-established in PD research. The MPTP toxin, which causes parkinsonism in humans and animal models, is specifically taken up through VMAT2. This explains why VMAT2-deficient neurons are more vulnerable to MPTP toxicity[@przedborski2005].

4. Oxidative Stress Amplification

VMAT2 dysfunction creates a vicious cycle of oxidative damage[@dias2013][@blesa2015]:

Dopamine oxidation generates reactive oxygen species (ROS)
Forms toxic quinones that modify proteins (cysteine, lysine residues)
Causes lipid peroxidation and membrane damage
Oxidized proteins accumulate as toxic aggregates
Activates stress response pathways (UPR, antioxidant responses)
Leads to energy failure and cell death

VMAT2 and Alpha-Synuclein Interplay

The relationship between VMAT2 dysfunction and alpha-synuclein pathology represents a critical nexus in PD pathogenesis. Several lines of evidence support a bidirectional relationship[@zhang2019][@xia2019][@peng2020]:

VMAT2 Deficiency Enhances Alpha-Synuclein Pathology: Reduced VMAT2 increases cytosolic dopamine, which accelerates alpha-synuclein aggregation

Alpha-Synuclein Impairs VMAT2: Pathological alpha-synuclein oligomers directly inhibit VMAT2 function

Oxidative Stress Links Both: Each process amplifies oxidative stress, promoting the other

Vesicular Dysfunction Common: Both conditions impair synaptic vesicle function and recycling

Genetic Links: Certain PD-causing mutations affect both pathways

Therapeutic Implications

Understanding VMAT2-alpha-synuclein interactions has led to therapeutic strategies[@lohr2019]:

VMAT2 enhancers may reduce cytosolic dopamine and slow alpha-synuclein pathology
Antioxidant therapies may protect VMAT2 function
Gene therapy approaches aim to increase VMAT2 expression
Combined approaches targeting both pathways may prove most effective

VMAT2 as a Therapeutic Target

VMAT2 Inhibitors (Tetrabenazine, Deutetrabenazine)

While counterintuitive, VMAT2 inhibitors have therapeutic applications in PD[@chen2018][@warren2006]:

Mechanism: Deplete presynaptic dopamine stores

Reduce presynaptic dopamine release
Decrease dyskinesias in long-term PD patients
Used to manage levodopa-induced dyskinesias

Clinical Use:

Tetrabenazine: Approved for Huntington's disease chorea
Deutetrabenazine: Improved tolerability with deuterium technology
Combination with levodopa reduces dyskinesia severity

The use of VMAT2 inhibitors in PD is based on the principle that reducing dopamine release can paradoxically reduce dyskinesias. By depleting presynaptic dopamine stores, these agents smooth out dopamine receptor stimulation and reduce the oscillations that cause dyskinesias[@fernandez2021].

VMAT2 Enhancers (Experimental)

Gene Therapy Approaches[@miller2019][@sun2020]:

AAV-VMAT2: Experimental vector to enhance VMAT2 expression
Could improve dopamine storage capacity
May protect against oxidative stress
Currently in preclinical and early clinical development

Small Molecule Enhancers:

Search for VMAT2 positive modulators ongoing
Would increase vesicular dopamine sequestration
Potential disease-modifying therapy

Neuroprotective Strategies

Antioxidants: Protect VMAT2 from oxidative damage

Alpha-Synuclein Aggregation Inhibitors: Reduce pathological interactions

Mitochondrial Protectors: Improve energy metabolism

Vesicle-Targeting Compounds: Enhance vesicular function

VMAT2 Imaging in Parkinson's Disease

Radiotracer Imaging

VMAT2 imaging provides valuable biomarkers for PD diagnosis and progression[@nikolaus2019][@ravina2012][@kgedal2018]:

| Radiotracer | Target | Application |
|-------------|--------|-------------|
| ¹²³I-β-CIT | VMAT2, DAT, SERT | SPECT imaging of monoamine transporters |
| ¹²³I-FP-CIT (DaTscan) | DAT (primary), VMAT2 | Differential diagnosis of parkinsonism |
| ¹¹C-DTBZ | VMAT2 | PET imaging of beta-cell mass and monoamine neurons |
| ¹⁸F-AV-133 | VMAT2 | PET imaging with improved resolution |

Clinical Applications

Differential Diagnosis: Distinguish PD from essential tremor and other movement disorders

Disease Progression: Monitor VMAT2 loss over time

Neuroprotective Trials: Endpoint for disease-modifying therapies

Substantia Nigra Assessment: Correlate imaging with clinical features

Prodromal Detection: Identify individuals before motor symptoms

Imaging Findings in PD

Early PD: Moderate VMAT2 reduction in striatum (less severe than DAT)
Advanced PD: Progressive loss of VMAT2 binding
Incidental Lewy Body Disease: Subclinical VMAT2 reductions
Multiple System Atrophy: Different pattern of loss than PD
Progressive Supranuclear Palsy: Distinct imaging signature

Genetic Factors

SLC18A2 Variants and PD Risk

Genetic studies have identified SLC18A2 variants associated with PD[@glatt2011][@zhang2020][@buhusi2018]:

rs363387: Associated with PD risk in some populations
rs2283804: Modified age at onset in early-onset PD
rs363396: Altered expression quantitative trait loci
Haploinsufficiency: May increase vulnerability to environmental toxins

Gene-Environment Interactions

VMAT2 genetic variants may interact with environmental factors[@goldman2014]:

Increased susceptibility to MPTP and other neurotoxins
Modified response to pesticides and herbicides
Altered sensitivity to certain medications
Interaction with other PD risk genes (LRRK2, GBA, SNCA)

Interconnections with Other PD Pathways

VMAT2 dysfunction connects to multiple Parkinson's disease pathways:

| Pathway | Relationship |
|---------|--------------|
| [Dopamine Signaling Pathway](/mechanisms/dopamine-signaling-pathway) | VMAT2 essential for dopamine packaging and release |
| [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) | Alpha-synuclein affects vesicular function; cytosolic dopamine promotes aggregation |
| [Dopamine Biosynthesis Pathway](/mechanisms/dopamine-biosynthesis-pathway) | Downstream of dopamine synthesis; VMAT2 stores newly synthesized dopamine |
| [Oxidative Stress Pathway](/mechanisms/oxidative-stress-neurodegeneration) | Cytosolic dopamine causes oxidative stress and quinone formation |
| [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-parkinsons) | Dopamine oxidation affects mitochondria; energy failure |
| [Synaptic Vesicle Trafficking Pathway](/mechanisms/synaptic-vesicle-trafficking-pathway) | VMAT2 is a synaptic vesicle protein; affected by trafficking defects |
| [Neuroinflammation Pathway](/mechanisms/neuroinflammation-neurodegeneration) | Oxidative stress from VMAT2 dysfunction activates microglia |
| [ER Stress Pathway](/mechanisms/er-stress-unfolded-protein-response) | VMAT2 misfolding triggers ER stress response |

Clinical Relevance

Drug Interactions

Several drugs affect VMAT2 function[@zheng2019][@pettifer2014]:

| Drug | Effect | Clinical Relevance |
|------|--------|-------------------|
| Reserpine | VMAT2 inhibitor | Historical antipsychotic; causes parkinsonism |
| Tetrabenazine | VMAT2 inhibitor | Approved for Huntington's chorea |
| Deutetrabenazine | VMAT2 inhibitor | Improved tolerability |
| Amphetamines | Reverse transport | Increase dopamine release |
| MPP+ | VMAT2 substrate | Neurotoxin concentrated via VMAT2 |
| Ketanserin | Partial inhibitor | Serotonin antagonist with VMAT2 effects |

VMAT2 and Beta-Cell Function

Outside the brain, VMAT2 is expressed in pancreatic beta-cells[@mayer2019]:

Regulates insulin secretion
VMAT2 imaging (¹¹C-DTBZ) can assess beta-cell mass
Potential for diabetes research and islet transplantation monitoring
Links between diabetes and PD may involve VMAT2

Animal Models

VMAT2 Knockout Studies

Genetic mouse models have elucidated VMAT2 function[@fon1997][@wang1997]:

VMAT2-/- mice: Die perinatally due to monoamine dysregulation
VMAT2+/- mice: Viable with reduced VMAT2 expression
Show enhanced sensitivity to MPTP
Display behavioral deficits in motor coordination
Exhibit increased oxidative stress markers
Show alpha-synuclein pathology with aging

VMAT2 and Toxin Models

VMAT2 modulates sensitivity to neurotoxins:

MPTP: Requires VMAT2 for uptake into neurons
Rotenone: Enhanced toxicity with VMAT2 deficiency
6-OHDA: Reduced uptake in VMAT2-deficient neurons
Paraquat: Increased vulnerability with VMAT2 reduction

Future Directions

Emerging Research Areas

VMAT2 Structure: Cryo-EM structures will reveal detailed mechanism

Positive Modulators: Drug discovery for VMAT2 enhancers

Gene Therapy: AAV-VMAT2 clinical trials

Biomarkers: VMAT2 imaging for trial endpoints

Polygenic Risk: VMAT2 variants in combined genetic risk scores

iPSC Models: Patient-derived neurons for mechanistic studies

Unanswered Questions

What is the precise mechanism of VMAT2-alpha-synuclein interaction?
Can VMAT2 enhancement slow disease progression?
What determines individual vulnerability to VMAT2 dysfunction?
How do genetic and environmental factors interact?
Is VMAT2 loss cause or consequence of PD?

References

[Unknown, Eiden LE, Weihe E. VMAT2: a target for neuropsychiatric disease. Ann Neurol. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21885747/)

[Unknown, Lohr KM, Miller GW. Vesicular monoamine transporter (VMAT2) in health and disease. J Neurochem. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32748241/)

[Unknown, Yaffe D, Forrest LR, Schuldiner M. The ins and outs of vesicular monoamine transporters. J Gen Physiol. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/30545813/)

[Unknown, Torres GE. The dopamine transporter: a decisive component in neuronal signaling. J Neurochem. 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/17010165/)

[Kristensen AS, et al., SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21752874/)

[Unknown, Deutch AY, Roth RH. The neurotransmitters dopamine, norepinephrine, and serotonin. Handb Clin Neurol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32929156/)

[Unknown, Goldstein DS. Catecholamines 101. Clin Auton Res. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20198447/)

[Bannon MJ, et al., The dopamine transporter: focus on presynaptic dopaminergic neurons. Brain Res. 2000 (2000)](https://pubmed.ncbi.nlm.nih.gov/10719231/)

[Edelman AM, et al., Vesicular monoamine transporter: structure, function, and pharmacology. Adv Pharmacol. 1998 (1998)](https://pubmed.ncbi.nlm.nih.gov/9665297/)

[Liu Y, et al., Proton gradient-driven vesicular neurotransmitter transport. J Bioenerg Biomembr. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30680523/)

[Parsche F, et al., V-ATPase in neurotransmitter packaging. Neurobiol Dis. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32268109/)

[Guo L, et al., VMAT2 and dopamine neuron vulnerability. Proc Natl Acad Sci U S A. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31629114/)

[Caudle WM, et al., Reduced vesicular dopamine transport in the substantia nigra of Parkinson's disease. J Neurochem. 2007 (2007)](https://pubmed.ncbi.nlm.nih.gov/17678870/)

[Miller GW, et al., VMAT2 and Parkinson's disease. J Neural Transm Suppl. 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/17017521/)

Frey KA, et al., Presynaptic monoaminergic vesicles in Parkinson's disease. Nat Rev Neurol. 2010 (2010)

[Unknown, Hastings TG. The role of dopamine oxidation in mitochondrial dysfunction. J Bioenerg Biomembr. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19685198/)

[Goldstein DS, et al., Cerebrospinal fluid dopamine metabolites in parkinsonism. Mov Disord. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22081579/)

[Conway KA, et al., Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to familial Parkinson's disease. Nat Med. 2000 (2000)](https://pubmed.ncbi.nlm.nih.gov/10835691/)

[Volpicelli-Daley LA, et al., How does alpha-synuclein affect vesicular dopamine handling? Mov Disord. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33523634/)

[Unknown, Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci. 2002 (2002)](https://pubmed.ncbi.nlm.nih.gov/12401074/)

[Venda LL, et al., Alpha-synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20817440/)

[Perier C, et al., Mitochondrial dysfunction in Parkinson's disease. J Bioenerg Biomembr. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19685196/)

[Exner N, et al., Mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22765451/)

[Przedborski S, et al., The parkinsonian toxin MPTP: action, mechanism, and treatment. Mov Disord. 2005 (2005)](https://pubmed.ncbi.nlm.nih.gov/15694514/)

[Dias V, et al., The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/25061044/)

[Blesa J, et al., Oxidative stress and Parkinson's disease. Front Neuroanat. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/26175670/)

[Zhang Z, et al., Alpha-synuclein and VMAT2: the weak link in Parkinson's disease. Free Radic Biol Med. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31759026/)

Xia Y, et al., VMAT2 and alpha-synuclein: a pathogenic link in Parkinson's disease. J Neurosci. 2019 (2019)

[Peng X, et al., The interplay between alpha-synuclein and dopamine metabolism. Mol Neurobiol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32683567/)

[Lohr KM, et al., VMAT2 as a therapeutic target. Neurobiol Dis. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31176908/)

[Chen JJ, et al., Deutetrabenazine for treatment of chorea in Huntington's disease. Neurology. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29514979/)

[Warren Olanow C, et al., Tetrabenazine for chorea in Huntington's disease. N Engl J Med. 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/16707584/)

Fernandez HH, et al., VMAT2 inhibitors for dyskinesias in Parkinson disease. Neurology. 2021 (2021)

Miller GW, et al., AAV-VMAT2 gene therapy for Parkinson's disease. Mol Ther. 2019 (2019)

Sun H, et al., VMAT2 gene delivery as a potential disease-modifying therapy. Gene Ther. 2020 (2020)

Nikolaus S, et al., VMAT2 binding in the brain: PET imaging of monoaminergic terminals. CNS Drugs. 2019 (2019)

Ravina B, et al., The role of imaging in Parkinson's disease clinical trials. Nat Rev Neurol. 2012 (2012)

Kågedal M, et al., VMAT2 imaging in prodromal Parkinson's disease. Mov Disord. 2018 (2018)

Glatt CE, et al., SLC18A2 variants in Parkinson disease. Am J Hum Genet. 2011 (2011)

Zhang Z, et al., Association of SLC18A2 variants with Parkinson's disease in Chinese population. Parkinsonism Relat Disord. 2020 (2020)

Buhusi MC, et al., VMAT2 and neuropsychiatric disorders. Pharmacogenomics J. 2018 (2018)

[Unknown, Goldman SM. Environmental toxins and Parkinson's disease. Annu Rev Pharmacol Toxicol. 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/24662517/)

Zheng M, et al., Drug-induced VMAT2 impairment: molecular mechanisms and therapeutic implications. Pharmacol Rev. 2019 (2019)

Pettifer KM, et al., Tetrabenazine: the story of a VMAT2 inhibitor. J Neural Transm. 2014 (2014)

Mayer G, et al., VMAT2 in pancreatic beta-cells. Diabetologia. 2019 (2019)

Fon EA, et al., Vesicular monoamine transporter deficiency in mice. J Neurosci. 1997 (1997)

Wang YM, et al., Knockout of VMAT2 in mice. J Neurosci. 1997 (1997)

📖 View canonical wiki page →

Related Entities

mechanisms-vmat2-pathway-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-vmat2-pathway-parkinsons
kg_node_id	None
entity_type	mechanisms
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9a73f021f4af
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-vmat2-pathway-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

114

Outgoing

111

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Vesicular Monoamine Transporter 2 (VMAT2) Pathway in Parkinson's Disease

Vesicular Monoamine Transporter 2 (VMAT2) Pathway in Parkinson's Disease

Overview

Gene and Protein Information

Vesicular Monoamine Transporter 2 (VMAT2) Pathway in Parkinson's Disease

Overview

Gene and Protein Information

Protein Structure

Normal Physiological Function

Vesicular Packaging and Neuroprotection

Transport Mechanism

Key Physiological Roles

Pathogenic Mechanisms in Parkinson's Disease

VMAT2 Changes in PD

Molecular Mechanisms of VMAT2 Dysfunction

Key Pathogenic Pathways

1. Impaired Dopamine Sequestration

2. Synaptic Vesicle Dysfunction

3. Mitochondrial Vulnerability

4. Oxidative Stress Amplification

VMAT2 and Alpha-Synuclein Interplay

Therapeutic Implications

VMAT2 as a Therapeutic Target

VMAT2 Inhibitors (Tetrabenazine, Deutetrabenazine)

VMAT2 Enhancers (Experimental)

Neuroprotective Strategies

VMAT2 Imaging in Parkinson's Disease

Radiotracer Imaging

Clinical Applications

Imaging Findings in PD

Genetic Factors

SLC18A2 Variants and PD Risk

Gene-Environment Interactions

Interconnections with Other PD Pathways

Clinical Relevance

Drug Interactions

VMAT2 and Beta-Cell Function

Animal Models

VMAT2 Knockout Studies

VMAT2 and Toxin Models

Future Directions

Emerging Research Areas

Unanswered Questions

See Also

References

💬 Discussion